Marker Therapeutics Inc MRKR

Healthcare Biotechnology

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.

NDAQ:MRKR - Post by User

Marker Therapeutics Inc

Bullboard Posts

Post by TheDon4on Nov 22, 2009 9:26pm

263 Views

Post# 16512761

SJ to help give Tap a lift.....

Rumor has it that StocksJournal is re-visiting this company with the help of a few of their over seas affiliates,
lets see how this plays out...been waiting a while now for this to break out,
best to all.

Bullboard Posts

Barrick Gold employees detained in Mali amid ongoing dispute